Objective To investigate the risk factors for colorectal cancer adjuvant chemotherapy induced leucopenia. Methods The basic clinical data of 108 patients with colorectal cancer who had received radical operation and adjuvant chemotherapy were retrospectively evaluated. The patients were divided into two groups: normal white blood cell group (39 patients) and leucopenia group (69 patients). The data were analyzed with SPSS 22.0 software, t test, χ2 test , univariate analysis and multifactor Logistic regression analysis, and analysis of variance to investigate the risk factors for colorectal cancer adjuvant chemotherapy induced leucopenia. Results Univariate analysis revealed that the female patients and the ones who received radiotherapy were more prone to leucopenia (P<0.01), while hypertension, the levels of white blood cell, neutrophil counting and serum creatinine before chemotherapy were protective factors for leucopenia (P<0.05 or<0.01). Multifactor Logistic regression analysis revealed that the level of serum creatinine before chemotherapy was an independent risk factor for leucopenia, OR = 0.950 (95% CI: 0.906- 0.996, P<0.05). The further analysis showed the lower the level of serum creatinine, the more severe the leucopenia would be (P = 0.04). Conclusions The level of serum creatinine before chemotherapy was an independent risk factor for colorectal cancer adjuvant chemotherapy induced leucopenia.

Objective To investigate the feasibility and efficacy of the intensity modulated radiotherapy (IMRT) with oral S-1 for locally advanced pancreatic cancer.Methods Forty-two patients with locally advanced pancreatic cancer were selected,and the patients were divided into 2 groups by random digits table method with 21 cases each.The patients in treatment group were treated by IMRT combined with oral S-1 40 mg/m2 twice daily from day 1 to day 14 of a 21-d cycle;the patients in control group were treated by IMRT combined with 30 min intravenous infusions of gemcitabine 1 000 mg/m2 on day 1,8,21 and 29.Radiation was concurrently delivered at a dose of 50.4 Gy (1.8 Gy/d,5 times per week,28 fractions).The dose of intensity modulated radiotherapy was 1.8 Gy/time (5 times/week,50.4 Gy/28 times).The recent curative effect and untoward reaction were assessed at the end of radiotherapy after 4 weeks.Results There were no statistical differences in efficient rate and disease control rate between treatment group and control group:57.1％ (12/21) vs.47.6％ (10/21) and 85.7％ (18/21) vs.76.2％ (16/21),P ＞ 0.05.The neutropenia rate and thrombocytopenia rate in treatment were significantly lower than those in control group:23.8％ (5/21) vs.57.1％ (12/21) and 28.6％ (6/21) vs.66.7％ (14/21),and there were statistical differences (P ＜ 0.05).There were no statistical differences in the incidences of anemia,nausea,vomiting,elevated aminotransferase and fatigue (P＞ 0.05).Conclusions The IMRT with oral S-1 for locally advanced pancreatic cancer is safe and effective.It is worthy of clinical promotion.

Objective To analyze the efficacy and safety of erlotinib associated conformal intensity modulated radiotherapy in treatment (IMRT) of locally advanced pancreatic carcinoma. Methods The clinical data of 23 patients with locally advanced pancreatic carcinoma were retrospectively analyzed. The patients′ therapeutic methods: erlotinib was taken continuously and orally at 100 mg/time, 1 time/d until disease progressed or serious adverse reactions happened; intensity modulated radiotherapy (IMRT) was used combined with erlotinib at 50.4 Gy, 1 time/d, 1.8 Gy/time, 5 times/week, total 28 times. Tumor response was evaluated at the end of radiotherapy after 4 weeks. Results In 23 patients, there was partial response in 10 cases, stable disease in 9 cases and progress disease in 4 cases. The objective response rate was 43.5%(10/23), and the median survival time was 11.3 months. Adverse reactions included fatigue, rash, bone marrow suppression, nausea and diarrhea. The adverse reactions were mostly tolerable with grade 1-2. Conclusions Erlotinib combined with IMRT is safe and effective in patients with locally advanced pancreatic carcinoma, which is worthy of further study.

Objective To evaluate the efficacy and safety of the gemcitabine(GEM) plus S-1 in unresectable cholangiocarcinoma. Methods Forty-nine unresectable cholangiocarcinoma patients from January 2010 to June 2014 were randomly divided into two groups. The experimental group contained 25 patients treated with gemcitabine and S-1 and the control group contained 24 patients treated with gemcitabine and cisplatin. Results The experimental group′s release rate (RR) and disease control rate (DCR) was 36.0% (9/25) and 76.0% (19/25),the control group′s was 25.0(6/24) and 58.3% (14/25), and there were no statistically significant differences (P=0.403 and 0.187). One-year survival rate for the experimental and the control groups were 40.0% (8/25) and 29.2% (7/24), and there was no statistically significant difference (P=0.426). Median overall survival (OS) in the experimental and control groups was 13.0 and 12.3 months, and there was no statistically significant difference (χ2=0.273, P=0.602). The rate ofⅠ～Ⅱgrade of oral mucositis was more higher than that in the control group [25.0%(6/24) vs. 4.0% (1/25), P=0.036 ]. Conclusions Combination of GEM and S-1 provides a better OS and response rate, and is safer.

Objective To evaluate the efficacy of mesalazine combined with compound glutamine in the treatment of radiation related enteritis. Methods Ninety-four patients were randomly divided into the observation group and the treatment group, with 47 cases in each group. Patients in control group were given compound glutamine orally. On the basis of compound glutamine, patients in the observation group was added mesalazine orally. Before and after treatment, all patients were assessed according to acute radiation injury grading (RTOG), and the quality of life (QOL) scale for cancer patients was used to evaluate the improvement of quality of life. Results The total effective rate of the observation group was 95.7％(45/47) , and that of the control group was 78.7％(37/47).The difference was statistically significant (P<0.05). At the end of radiation therapy, patients in the observation group showed significant superiority in quality of life (P<0.05). Conclusions Mesalazine combined with compound glutamine in the treatment of radiation-associated enteritis has advantages and can improve the quality of life.